These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 15904629)

  • 1. Relation of progression of coronary artery atherosclerosis to risk of cardiovascular events (from the Monitored Atherosclerosis Regression Study).
    Vigen C; Hodis HN; Selzer RH; Mahrer PR; Mack WJ
    Am J Cardiol; 2005 Jun; 95(11):1277-82. PubMed ID: 15904629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial quantitative coronary angiography and coronary events.
    Mack WJ; Xiang M; Selzer RH; Hodis HN
    Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
    Waters D; Higginson L; Gladstone P; Kimball B; Le May M; Boccuzzi SJ; Lespérance J
    Circulation; 1994 Mar; 89(3):959-68. PubMed ID: 8124836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).
    Kleemann A; Eckert S; von Eckardstein A; Lepper W; Schernikau U; Gleichmann U; Hanrath P; Fleck E; Neiss A; Kerber S; Assmann G; Breithardt G;
    Eur Heart J; 1999 Oct; 20(19):1393-406. PubMed ID: 10487800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.
    Domanski M; Tian X; Fleg J; Coady S; Gosen C; Kirby R; Sachdev V; Knatterud G; Braunwald E
    Am J Cardiol; 2008 Oct; 102(8):1023-7. PubMed ID: 18929703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cystatin C levels on angiographic atherosclerosis progression and events among postmenopausal women with angiographically decompensated coronary artery disease (from the Women's Angiographic Vitamin and Estrogen [WAVE] study).
    Patel D; Ahmad S; Silverman A; Lindsay J
    Am J Cardiol; 2013 Jun; 111(12):1681-7. PubMed ID: 23499273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
    Rackley CE
    Clin Cardiol; 1996 Sep; 19(9):683-9. PubMed ID: 8874986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM
    Atheroscler Suppl; 2007 Aug; 8(2):3-8. PubMed ID: 17588826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting.
    Ezhov MV; Safarova MS; Afanasieva OI; Kukharchuk VV; Pokrovsky SN
    Atherosclerosis; 2014 Aug; 235(2):477-82. PubMed ID: 24952151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-year outcomes of patients randomized to surgery, angioplasty, or medical treatment for stable multivessel coronary disease: effect of age in the Medicine, Angioplasty, or Surgery Study II trial.
    Rezende PC; Hueb W; Garzillo CL; Lima EG; Hueb AC; Ramires JA; Kalil Filho R
    J Thorac Cardiovasc Surg; 2013 Nov; 146(5):1105-12. PubMed ID: 22944095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
    Waters D; Higginson L; Gladstone P; Kimball B; LeMay M; Lespérance J
    Control Clin Trials; 1993 Feb; 14(1):45-74. PubMed ID: 8440094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study.
    Dens JA; Desmet WJ; Coussement P; De Scheerder IK; Kostopoulos K; Kerdsinchai P; Supanantaroek C; Piessens JH
    Heart; 2003 Aug; 89(8):887-92. PubMed ID: 12860866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS).
    Lancet; 1994 Sep; 344(8923):633-8. PubMed ID: 7864934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS).
    Zhao XQ; Krasuski RA; Baer J; Whitney EJ; Neradilek B; Chait A; Marcovina S; Albers JJ; Brown BG
    Am J Cardiol; 2009 Dec; 104(11):1457-64. PubMed ID: 19932775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective natural-history study of coronary atherosclerosis.
    Stone GW; Maehara A; Lansky AJ; de Bruyne B; Cristea E; Mintz GS; Mehran R; McPherson J; Farhat N; Marso SP; Parise H; Templin B; White R; Zhang Z; Serruys PW;
    N Engl J Med; 2011 Jan; 364(3):226-35. PubMed ID: 21247313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy.
    Raggi P; Callister TQ; Shaw LJ
    Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1272-7. PubMed ID: 15059806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.